Lifeboat Foundation

Boston-based biotech Vincere Biosciences is on a mission to combat neurodegenerative disease by improving the quality of the mitochondria in our cells. The company was spun out from AI drug discovery company NeuroInitiative in 2018 after its platform identified that modulation of certain enzymes to repair mitochondrial health “may slow or stop the progression of Parkinson’s disease and other age-related disorders.”

In addition to seed funding, Vincere has received grants from the National Institutes of Health and Michael J Fox Foundation, and the company is now gearing up for a Series A funding round in early 2022.

Longevity. Technology: Mitochondria’s role in longevity is a hot topic. Often referred to as the “powerhouse of the cell”, these miniature organs within our cells play a key role in providing the energy needed for growth, repair and rejuvenation. As we age, our mitochondria begin to decline in function, and this decline is linked to a range of age-related diseases. We caught up with Vincere’s co-founder and CEO Dr Spring Behrouz to find out how her company aims to tap into the potential of these small but mighty biological players.

https://skl.sh/isaacarthur03211
Perhaps the most sought after technology is not the ability to extend life, but to restore it once it is gone. We will examine the technological options that may be available to us in the future.

Visit our Website: http://www.isaacarthur.net.
Support us on Patreon: https://www.patreon.com/IsaacArthur.
Facebook Group: https://www.facebook.com/groups/1583992725237264/
Reddit: https://www.reddit.com/r/IsaacArthur/
Twitter: https://twitter.com/Isaac_A_Arthur on Twitter and RT our future content.
SFIA Discord Server: https://discord.gg/53GAShE

Continue reading “Resurrection: The first 1,000 people to use the link will get a free trial of Skillshare Premium Membership:” »

Monash University, Australia scientists have discovered an enzyme that is key to why exercise improves our health. Importantly this discovery has opened up the possibility of drugs to promote this enzyme’s activity, protecting against the consequences of aging on metabolic health, including type 2 diabetes.

The proportion of people worldwide over 60 years old will double in the next three decades and by 2031, more than six million Australians will be over 65 years old. The incidence of type 2 diabetes increases with age so this aging population will also result in an increased incidence of the disease globally.

One of the main reasons for the increased prevalence of type 2 diabetes with age is the development of insulin resistance, or an inability for the body to respond to insulin, and this is often caused by reduced physical activity as we age.

In this video Dr. Lustgarten introduces his N of 1 experiment and gives an overview of the processes that he follows. He also discusses why he thinks it is important to track your own markers and not just rely on published trials.

Dr. Michael Lustgarten is a scientist at the Tufts University Human Nutrition Research Center on Aging in Boston, Massachusetts. His research currently focuses on the role of the gut microbiome and serum metabolome on muscle mass and function in older adults.
In this series of interviews Dr Lustgarten shares his experience with his rigorous n of 1 experiment over the last 7 years and shows how we or anyone can conduct a similar trial by tracking food, exercise and sleep, measure results and derive relationships between them, with a goal of extending our healthspan.

Continue reading “N Of 1 Extend Lifespan Experiment: How To Start | Dr Michael Lustgarten Interview Series 3 Ep 1” »

A stem cell researcher who founded his startup with the psychedelic-loving German billionaire Christian Angermayer, Peyer believes that aging is a disease that humans can fight with pharmaceuticals. He plans to prove it first by identifying disorders and diseases that mimic aging, such as those that cause loss of muscle mass, and then partner with researchers studying medicines for said diseases.

A bold proposal: that by 2050, a 70-year-old will look and feel like they’re 50.

That’s the gamble that 35-year-old James Peyer is taking with this Cambrian Biopharma “longevity startup,” the Times of London reports.

Continue reading “Tech Bro Thinks He’s Close to Cheating Death” »

Sorry if re-post…

A team of researchers affiliated with a large number of institutions in Japan has developed a vaccine that tricks the immune system into removing senescent cells. In their paper published in the journal Nature Aging, the group describes their vaccine, how it works and how effective it was when given to test mice.

Prior research has shown that part of the aging process is the development of senescent cells —cells that outlive their usefulness but fail to die naturally. Instead, they produce chemicals that can lead to inflammation, aging and a host of other ailments. Prior research has shown that senescence occurs when cells stop dividing. Prior research has also shown that senescent cells can lead to tumor growth in some instances and tumor suppression in others. Senescence also plays a role in tissue repair, and its impacts on the body vary depending on factors such as overall health and age. It is suspected that senescence is related to telomere erosion, and in some cases, environmental factors that lead to cell damage. In this new effort, the researchers have developed a vaccine that creates antibodies that attach to senescent cells, marking them for removal by white blood cells.

Continue reading “A new vaccine that alters senescent cells in a way that pushes the immune system into removing them” »

Yesterday’s longevity AMA: michael lustgarten, phd.

Questionsabout yesterday’s video, and more…AMA!

Continue reading “AMA Live Stream #1” »

Contrary to what you may think, getting old is not inevitable. And by getting old, I mean the bad parts: weakened muscles, fading memory, aching joints … or perhaps a disease such as cancer or diabetes makes an unwelcome appearance.

James Peyer, 35, is out to prove that age is, instead, like polio or tuberculosis. Those and other infectious diseases once were the biggest killers, until we developed effective vaccines or treatments.

Why, asked Peyer, co-founder of the New York longevity start-up Cambrian Biopharma, should age be any different? “Of our 100,000-year-plus history as a species, it’s been for only about 75 years that these diseases of ageing have been the primary predators of humankind.” He added: “We are rapidly zeroing in on our biggest.

How regenerative medicine promises to slow, or even reverse cognitive decline.